|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Non-interventional management of resistant hypertension显示文摘Hypertension is one of the most popular fields of re-search in modern medicine due to its high prevalence and its major impact on cardiovascular risk and con-sequently on global health. Indeed, about one third of individuals worldwide has hypertension and is under increased long-term risk of myocardial infarction, stroke or cardiovascular death. On the other hand, resistant hypertension, the 'uncontrollable' part of arterial hy-pertension despite appropriate therapy, comprises a much greater menace since long-standing, high levels of blood pressure along with concomitant debilitating entities such as chronic kidney disease and diabetes mellitus create a prominent high cardiovascular risk milieu. However, despite the alarming consequences, resistant hypertension and its effective management still have not received proper scientific attention. As-pects like the exact prevalence and prognosis are yet tobe clarified. In an effort to manage patients with resis-tant hypertension appropriately, clinical doctors are still racking their brains in order to find the best therapeutic algorithm and surmount the substantial difficulties in controlling this clinical entity. This review aims to shed light on the effective management of resistant hyper-tension and provide practical recommendations for cli-nicians dealing with such patients. | Michael Doumas Costas Tsioufis Charles Faselis Antonios Lazaridis Haris Grassos Vasilios Papademetriou | 2014 | World Journal of Cardiology2014，6，10： | 5 |
| 2 | Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients:a meta-analysis of randomized clinical trials显示文摘BACKGROUND Sodium-glucose co-transporter-2 inhibitors(SGLT2i)significantly reduce the risk of cardiovascular(CV)and renal adverse events in patients with diabetes mellitus,heart failure(HF)and/or chronic kidney disease.We performed a meta-analysis to explore the impact of several different SGLT2i on all-cause mortality,CV mortality,HF hospitalizations and the combined outcome CV death/HF hospitalization in HF patients across the spectrum of left ventricular ejection fraction(LVEF)phenotypes.METHODS A systematic search in MEDLINE database and Cochrane library through March 2021 was performed without limitations.Randomized clinical trials that provided data about the impact of SGLT2i on all-cause mortality,CV mortality,HF hospitalizations or the combined outcome of CV death/HF hospitalization in HF patients were included.A random effects model was used for calculating the effect estimates.RESULTS Nine studies(n=16,723 patients,mean age:65.9 years,males:70.7%)were included in the quantitative synthesis.Compared to placebo,SGLT2i use was associated with 14%lower risk of all-cause mortality[hazard ratio(HR)=0.86,95%CI:0.78−0.94,I^(2)=0,P=0.0008],32%lower risk of HF hospitalizations(HR=0.68,95%CI:0.62−0.74,I^(2)=0,P<0.001),14%lower risk of CV mortality(HR=0.86,95%CI:0.77−0.95,I^(2)=0,P=0.003)and 26%lower risk of CV death/HF hospitalization(HR=0.74,95%CI:0.68−0.80,I^(2)=0,P<0.001).Regarding the safety outcomes,our data revealed no significant differences between SGLT2i and placebo groups in drug related discontinuations,amputations,severe hypoglycemia,hypotension,volume depletion,ketoacidosis and genital infections.By contrast,a protective role of SGLT2i against placebo was found for serious adverse events and acute kidney injury.CONCLUSIONS In patients with HF,regardless of LVEF phenotype,all SGLT2i had an excellent safety profile and significantly reduced the risk of all-cause mortality,CV mortality,HF hospitalizations and CV deaths/HF hospitalizations compared to placebo. | George Bazoukis Stamatis S.Papadatos Costas Thomopoulos Gary Tse Stefanos Cheilidis Konstantinos Tsioufis Dimitrios Farmakis | 2021 | Journal of Geriatric Cardiology2021，18，10： | 3 |
| 3 | Carotid artery disease as amarker for the presence of severe coronary artery disease in patients evaluated for chest pain显示文摘 | Kallikazaros I Tsioufis C Sideris S | 1999 | Stroke1999，30，5： | 1 |
| 4 | Myocardial and aortic stiffening in the early course of primary aldosteronism 显示文摘 | Tsioufis C Tsiachris D Dimitriadis K | 2008 | Clin Cardiol2008，31，9： | 1 |
| 5 | Closed relation between carotid and ascending aortic atherosclerosis in cardiac patients显示文摘 | Kallikazaros IE Tsioufis CP Stefanadis CI | 2000 | Circulation2000，102，193： | 1 |
| 6 | Comparative prog- nostic role of nighttime blood pressure and nondipping profile on renal outcomes 显示文摘 | Tsioufis C Andrikou I Thomopoulos C | 2011 | Am J Nephrol2011，33，3： | 1 |
| 7 | Renal and cardi- ac effects of renal sympathetic denervation and carotid barorecep- tor stimulation 显示文摘 | Tsioufis C Dimitriadis K Thomopoulos C | 2014 | Curt Vasc Pharmaco12014，12，1： | 1 |
| 8 | A footprint ofBrucella infection: enormous saccular aneurysm of theascending aorta显示文摘 | Tsioufis K Stefanadis C Kallikazaros I | 2006 | Heart2006，92，9： | 1 |
| 9 | Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension显示文摘 | Dimitriadis K Chatzis D | 2005 | Am J Cardiol2005，96，： | 1 |
| 10 | Periodontitisand blood pressure: the concept of dental hypertension 显示文摘 | Tsioufis C Kasiakogias A Thomopoulos C | | Ath-erosclerosis0，219，1： | 1 |
| 11 | Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension:the EnligHTN I trial显示文摘 | Worthley SG Tsioufis CP Worthley MI | 2013 | Eur Heart J2013，34，28： | 1 |
| 12 | Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain显示文摘 | Kallikazaros I Tsioufis C Sideris S | 1999 | Stroke1999，30，： | 1 |
| 13 | Exercise blood pressure response, albuminuria, and arterial stiffness in hypertension显示文摘 | Tsioufis C Dimitriadis K Thomopoulos C | 2008 | Am J Med2008，121，： | 1 |
| 14 | The incremental effect of obstructive sleep apnea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects显示文摘 | Thomopoulos K Dimitriadisk | 2007 | J Hypertens2007，25，： | 1 |
| 15 | Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain显示文摘 | Kallikazaros I Tsioufis C Sideris S | 1999 | Stroke1999，30，5： | 1 |
| 16 | Renal nerve ablation for resistant hypertension : how did we get here, present status, and future directions 显示文摘 | Papademetriou V Rashidi AA Tsioufis C | 2014 | Circulation2014，129，13： | 1 |
| 17 | Prognostic clinical and angiographic characteristics for the development of a new significant lesion in remote segments after successful percutaneous coronary intervention显示文摘 | E. Tsiamis K. Toutouzas A. Synetos J. Karambelas A. Karanasos C. Demponeras M. Drakopoulou E. Stefanadi C. Tsioufis D. Tousoulis C. Stefanadis | 2008 | International Journal of Cardiology2008，，1： | 1 |
| 18 | Relation of microalbuminuria to adiponectin and aug-mented C-reactive protein levels in men with essential hypertension显示文摘 | TSIOUFIS C DIMITRIADIS K CHATZIS D | 2005 | Am J Cardiol2005，96，： | 1 |
| 19 | ADMA, C-reactive protein, and albu- minuria in untreated essential hyperten- sion: a cross-sectional study显示文摘 | Tsioufis C Dimitriadis K Andrikou E etal | 2010 | Am J Kid- ney Dis2010，55，6： | 1 |
| 20 | Microalhuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects显示文摘 | Tsioufis C Stefanadis C Toutouza M | 2002 | J Hum Hypertens2002，16，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员